Palvella Therapeutics (NASDAQ:PVLA) COO Sells $476,360.46 in Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total transaction of $476,360.46. Following the sale, the chief operating officer owned 2,154 shares of the company’s stock, valued at approximately $238,512.42. The trade was a 66.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Palvella Therapeutics Trading Up 9.4%

Palvella Therapeutics stock opened at $129.84 on Thursday. Palvella Therapeutics, Inc. has a 12 month low of $20.35 and a 12 month high of $151.18. The business’s 50 day simple moving average is $118.25 and its 200 day simple moving average is $109.69. The company has a market cap of $1.86 billion, a price-to-earnings ratio of -31.14 and a beta of -0.15.

Palvella Therapeutics (NASDAQ:PVLA) last released its earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). As a group, equities research analysts forecast that Palvella Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Chardan Capital restated a “buy” rating and issued a $240.00 price objective on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Wall Street Zen downgraded shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Stephens reissued an “overweight” rating and issued a $220.00 price target on shares of Palvella Therapeutics in a research report on Thursday, May 21st. HC Wainwright upped their price target on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Finally, Mizuho raised their price objective on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $199.53.

Hedge Funds Weigh In On Palvella Therapeutics

A number of large investors have recently modified their holdings of the company. Avidity Partners Management LP grew its holdings in shares of Palvella Therapeutics by 262.7% during the 1st quarter. Avidity Partners Management LP now owns 70,000 shares of the company’s stock valued at $8,726,000 after purchasing an additional 50,700 shares during the last quarter. Arete Wealth Advisors LLC bought a new stake in Palvella Therapeutics in the first quarter worth $2,178,000. Bank of America Corp DE boosted its position in Palvella Therapeutics by 25.4% during the first quarter. Bank of America Corp DE now owns 37,972 shares of the company’s stock valued at $4,733,000 after buying an additional 7,700 shares during the period. The Manufacturers Life Insurance Company boosted its position in Palvella Therapeutics by 688.9% during the first quarter. The Manufacturers Life Insurance Company now owns 17,907 shares of the company’s stock valued at $2,232,000 after buying an additional 15,637 shares during the period. Finally, First Light Asset Management LLC grew its stake in shares of Palvella Therapeutics by 38.3% during the first quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock valued at $122,251,000 after buying an additional 271,617 shares during the last quarter. 40.11% of the stock is owned by hedge funds and other institutional investors.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.